TD Cowen analyst Ryan Langston maintained a Buy rating on Addus Homecare today and set a price target of $140.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ryan Langston has given his Buy rating due to a combination of factors tied to Addus Homecare’s earnings outlook and valuation. He modestly raised his first‑quarter 2026 general and administrative expense forecast, aligning it with the company’s usual seasonal cost pattern as a percentage of revenue, but did not view this as thesis‑changing for the broader earnings trajectory.
He kept his full‑year 2026 adjusted EBITDA projection intact, reflecting confidence that cost of services should remain stable while the firm benefits from incremental operating leverage in overhead. Based on these assumptions, he maintained his $140 price target, which is derived from applying a 12.3x multiple to his 2027 EBITDA excluding non‑controlling interest estimate, supporting a Buy recommendation given the implied upside potential.
Langston covers the Healthcare sector, focusing on stocks such as HCA Healthcare, UnitedHealth, and Universal Health. According to TipRanks, Langston has an average return of -5.1% and a 36.67% success rate on recommended stocks.